TABLE 1.
Prevalence of viral suppression among persons aged ≥13 years who had HIV infection diagnosed in 2010 and were retained in care* (N = 1,340), by selected characteristics — Georgia†
| Characteristic | Persons with diagnosed HIV | Viral suppression | ||
|---|---|---|---|---|
|
|
|
|||
| No. | % | No. | % | |
| Overall | 1,340 | 100.0 | 958 | 71.5 |
| Race/Ethnicity | ||||
| Black | 720 | 53.7 | 456 | 63.3 |
| White | 149 | 11.1 | 116 | 78.2 |
| Hispanic | 78 | 5.8 | 61 | 77.9 |
| Other/Unknown | 393 | 29.3 | 325 | 82.7 |
| Age group (yrs) § | ||||
| 13–24 | 255 | 19.0 | 144 | 56.5 |
| 25–34 | 366 | 27.3 | 258 | 70.5 |
| 35–44 | 307 | 22.9 | 229 | 74.6 |
| 45–54 | 290 | 21.6 | 228 | 78.6 |
| ≥55 | 122 | 9.0 | 99 | 81.2 |
| Disease stage at diagnosis ¶ | ||||
| 1 | 211 | 15.8 | 136 | 64.5 |
| 2 | 336 | 25.1 | 243 | 72.3 |
| 3 | 375 | 28.0 | 302 | 80.5 |
| Unknown | 418 | 31.2 | 277 | 66.3 |
| Transmission category ** | ||||
| Male | 1,033 | 77.1 (100.0) | 740 | 71.6 |
| Male-to-male sexual contact | 638 | 47.6 (61.7) | 418 | 65.5 |
| Injection drug use | 30 | 2.3 (3.0) | 20 | 65.3 |
| Male-to-male sexual contact and injection drug use | 15 | 1.1 (1.5) | 10 | 66.7 |
| Heterosexual contact | 46 | 3.4 (4.4) | 35 | 77.4 |
| Other/Unknown†† | 304 | 22.7 (29.4) | 257 | 84.5 |
| Female | 307 | 22.9 (100.0) | 218 | 71.0 |
| Injection drug use | 43 | 3.2 (13.4) | 33 | 78.6 |
| Heterosexual contact | 208 | 15.6 (67.9) | 142 | 67.9 |
| Other/Unknown†† | 56 | 4.2 (18.3) | 43 | 76.8 |
Retained in care defined as having at least two laboratory tests (CD4+ or viral load) at least 3 months apart during 4–15 months after diagnosis.
Among persons residing in Georgia and having a positive Western Blot or viral load based on surveillance data reported during 2010. Viral suppression defined as viral load <200 on the basis of most recent test during 4–15 months after diagnosis. Only includes persons with their sex recorded at birth.
Age based on the person’s age at year’s end 2010.
Based on first recorded CD4+ cell count ≤3 months after diagnosis. Defined as stage 1: CD4+ count ≥500 cells/μL or CD4+ percentage of total lymphocytes ≥29; stage 2: CD4+ count of 200–499 cells/μL or CD4+ percentage of total lymphocytes of 14–28; and stage 3: CD4+ count of <200 cells/μL or CD4+ percentage of total lymphocytes of <14.
Data by transmission category have been statistically adjusted to account for missing transmission category. Nested percentages indicate percentages among newly diagnosed persons of specified sex.
Includes hemophilia, blood transfusion, perinatal exposure, or risk factor unknown or not indicated.